[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Cannabinoid Derived Pharmaceutical Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

April 2023 | 112 pages | ID: G72CE3A8DE5BEN
GlobalInfoResearch

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
According to our (Global Info Research) latest study, the global Cannabinoid Derived Pharmaceutical market size was valued at USD 909.6 million in 2022 and is forecast to a readjusted size of USD 1994.1 million by 2029 with a CAGR of 11.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Cannabinoid Derived Pharmaceutical market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Cannabinoid Derived Pharmaceutical market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029

Global Cannabinoid Derived Pharmaceutical market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029

Global Cannabinoid Derived Pharmaceutical market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029

Global Cannabinoid Derived Pharmaceutical market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Cannabinoid Derived Pharmaceutical

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Cannabinoid Derived Pharmaceutical market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cara Therapeutics Inc, Arena Pharmaceuticals, Cannabics Pharmaceuticals Inc, Echo Pharmaceuticals and Gw Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Cannabinoid Derived Pharmaceutical market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
  • Cannabinoid Receptor Type 1 (CB1)
  • Cannabinoid Receptor Type 2 (CB2)
  • Others
Market segment by Application
  • Epilepsy
  • Migraine
  • Multiple Sclerosis
  • Others
Major players covered
  • Cara Therapeutics Inc
  • Arena Pharmaceuticals
  • Cannabics Pharmaceuticals Inc
  • Echo Pharmaceuticals
  • Gw Pharmaceuticals
  • Inmed Pharmaceuticals
  • Insys Therapeutics Inc
  • Larapharm
  • Mgc Pharmaceuticals Ltd
  • One World Cannabis
  • Orpheus Medica
  • Receptor Life Sciences
  • Respirerx Pharmaceuticals
  • Tetra Bio-Pharma
  • Cardiol Therapeutics
  • United Cannabis Corporation
  • Zynerba Pharmaceuticals
Market segment by region, regional analysis covers
  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Cannabinoid Derived Pharmaceutical product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Cannabinoid Derived Pharmaceutical, with price, sales, revenue and global market share of Cannabinoid Derived Pharmaceutical from 2018 to 2023.

Chapter 3, the Cannabinoid Derived Pharmaceutical competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cannabinoid Derived Pharmaceutical breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Cannabinoid Derived Pharmaceutical market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Cannabinoid Derived Pharmaceutical.

Chapter 14 and 15, to describe Cannabinoid Derived Pharmaceutical sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW

1.1 Product Overview and Scope of Cannabinoid Derived Pharmaceutical
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
  1.3.1 Overview: Global Cannabinoid Derived Pharmaceutical Consumption Value by Type: 2018 Versus 2022 Versus 2029
  1.3.2 Cannabinoid Receptor Type 1 (CB1)
  1.3.3 Cannabinoid Receptor Type 2 (CB2)
  1.3.4 Others
1.4 Market Analysis by Application
  1.4.1 Overview: Global Cannabinoid Derived Pharmaceutical Consumption Value by Application: 2018 Versus 2022 Versus 2029
  1.4.2 Epilepsy
  1.4.3 Migraine
  1.4.4 Multiple Sclerosis
  1.4.5 Others
1.5 Global Cannabinoid Derived Pharmaceutical Market Size & Forecast
  1.5.1 Global Cannabinoid Derived Pharmaceutical Consumption Value (2018 & 2022 & 2029)
  1.5.2 Global Cannabinoid Derived Pharmaceutical Sales Quantity (2018-2029)
  1.5.3 Global Cannabinoid Derived Pharmaceutical Average Price (2018-2029)

2 MANUFACTURERS PROFILES

2.1 Cara Therapeutics Inc
  2.1.1 Cara Therapeutics Inc Details
  2.1.2 Cara Therapeutics Inc Major Business
  2.1.3 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
  2.1.4 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.1.5 Cara Therapeutics Inc Recent Developments/Updates
2.2 Arena Pharmaceuticals
  2.2.1 Arena Pharmaceuticals Details
  2.2.2 Arena Pharmaceuticals Major Business
  2.2.3 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
  2.2.4 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.2.5 Arena Pharmaceuticals Recent Developments/Updates
2.3 Cannabics Pharmaceuticals Inc
  2.3.1 Cannabics Pharmaceuticals Inc Details
  2.3.2 Cannabics Pharmaceuticals Inc Major Business
  2.3.3 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product and Services
  2.3.4 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.3.5 Cannabics Pharmaceuticals Inc Recent Developments/Updates
2.4 Echo Pharmaceuticals
  2.4.1 Echo Pharmaceuticals Details
  2.4.2 Echo Pharmaceuticals Major Business
  2.4.3 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
  2.4.4 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.4.5 Echo Pharmaceuticals Recent Developments/Updates
2.5 Gw Pharmaceuticals
  2.5.1 Gw Pharmaceuticals Details
  2.5.2 Gw Pharmaceuticals Major Business
  2.5.3 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
  2.5.4 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.5.5 Gw Pharmaceuticals Recent Developments/Updates
2.6 Inmed Pharmaceuticals
  2.6.1 Inmed Pharmaceuticals Details
  2.6.2 Inmed Pharmaceuticals Major Business
  2.6.3 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
  2.6.4 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.6.5 Inmed Pharmaceuticals Recent Developments/Updates
2.7 Insys Therapeutics Inc
  2.7.1 Insys Therapeutics Inc Details
  2.7.2 Insys Therapeutics Inc Major Business
  2.7.3 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
  2.7.4 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.7.5 Insys Therapeutics Inc Recent Developments/Updates
2.8 Larapharm
  2.8.1 Larapharm Details
  2.8.2 Larapharm Major Business
  2.8.3 Larapharm Cannabinoid Derived Pharmaceutical Product and Services
  2.8.4 Larapharm Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.8.5 Larapharm Recent Developments/Updates
2.9 Mgc Pharmaceuticals Ltd
  2.9.1 Mgc Pharmaceuticals Ltd Details
  2.9.2 Mgc Pharmaceuticals Ltd Major Business
  2.9.3 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product and Services
  2.9.4 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.9.5 Mgc Pharmaceuticals Ltd Recent Developments/Updates
2.10 One World Cannabis
  2.10.1 One World Cannabis Details
  2.10.2 One World Cannabis Major Business
  2.10.3 One World Cannabis Cannabinoid Derived Pharmaceutical Product and Services
  2.10.4 One World Cannabis Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.10.5 One World Cannabis Recent Developments/Updates
2.11 Orpheus Medica
  2.11.1 Orpheus Medica Details
  2.11.2 Orpheus Medica Major Business
  2.11.3 Orpheus Medica Cannabinoid Derived Pharmaceutical Product and Services
  2.11.4 Orpheus Medica Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.11.5 Orpheus Medica Recent Developments/Updates
2.12 Receptor Life Sciences
  2.12.1 Receptor Life Sciences Details
  2.12.2 Receptor Life Sciences Major Business
  2.12.3 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product and Services
  2.12.4 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.12.5 Receptor Life Sciences Recent Developments/Updates
2.13 Respirerx Pharmaceuticals
  2.13.1 Respirerx Pharmaceuticals Details
  2.13.2 Respirerx Pharmaceuticals Major Business
  2.13.3 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
  2.13.4 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.13.5 Respirerx Pharmaceuticals Recent Developments/Updates
2.14 Tetra Bio-Pharma
  2.14.1 Tetra Bio-Pharma Details
  2.14.2 Tetra Bio-Pharma Major Business
  2.14.3 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product and Services
  2.14.4 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.14.5 Tetra Bio-Pharma Recent Developments/Updates
2.15 Cardiol Therapeutics
  2.15.1 Cardiol Therapeutics Details
  2.15.2 Cardiol Therapeutics Major Business
  2.15.3 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product and Services
  2.15.4 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.15.5 Cardiol Therapeutics Recent Developments/Updates
2.16 United Cannabis Corporation
  2.16.1 United Cannabis Corporation Details
  2.16.2 United Cannabis Corporation Major Business
  2.16.3 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product and Services
  2.16.4 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.16.5 United Cannabis Corporation Recent Developments/Updates
2.17 Zynerba Pharmaceuticals
  2.17.1 Zynerba Pharmaceuticals Details
  2.17.2 Zynerba Pharmaceuticals Major Business
  2.17.3 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
  2.17.4 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.17.5 Zynerba Pharmaceuticals Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: CANNABINOID DERIVED PHARMACEUTICAL BY MANUFACTURER

3.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Manufacturer (2018-2023)
3.2 Global Cannabinoid Derived Pharmaceutical Revenue by Manufacturer (2018-2023)
3.3 Global Cannabinoid Derived Pharmaceutical Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
  3.4.1 Producer Shipments of Cannabinoid Derived Pharmaceutical by Manufacturer Revenue ($MM) and Market Share (%): 2022
  3.4.2 Top 3 Cannabinoid Derived Pharmaceutical Manufacturer Market Share in 2022
  3.4.2 Top 6 Cannabinoid Derived Pharmaceutical Manufacturer Market Share in 2022
3.5 Cannabinoid Derived Pharmaceutical Market: Overall Company Footprint Analysis
  3.5.1 Cannabinoid Derived Pharmaceutical Market: Region Footprint
  3.5.2 Cannabinoid Derived Pharmaceutical Market: Company Product Type Footprint
  3.5.3 Cannabinoid Derived Pharmaceutical Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Cannabinoid Derived Pharmaceutical Market Size by Region
  4.1.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2029)
  4.1.2 Global Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2029)
  4.1.3 Global Cannabinoid Derived Pharmaceutical Average Price by Region (2018-2029)
4.2 North America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.3 Europe Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.4 Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.5 South America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.6 Middle East and Africa Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

5.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
5.2 Global Cannabinoid Derived Pharmaceutical Consumption Value by Type (2018-2029)
5.3 Global Cannabinoid Derived Pharmaceutical Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
6.2 Global Cannabinoid Derived Pharmaceutical Consumption Value by Application (2018-2029)
6.3 Global Cannabinoid Derived Pharmaceutical Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
7.2 North America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
7.3 North America Cannabinoid Derived Pharmaceutical Market Size by Country
  7.3.1 North America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
  7.3.2 North America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
  7.3.3 United States Market Size and Forecast (2018-2029)
  7.3.4 Canada Market Size and Forecast (2018-2029)
  7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
8.2 Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
8.3 Europe Cannabinoid Derived Pharmaceutical Market Size by Country
  8.3.1 Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
  8.3.2 Europe Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
  8.3.3 Germany Market Size and Forecast (2018-2029)
  8.3.4 France Market Size and Forecast (2018-2029)
  8.3.5 United Kingdom Market Size and Forecast (2018-2029)
  8.3.6 Russia Market Size and Forecast (2018-2029)
  8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Cannabinoid Derived Pharmaceutical Market Size by Region
  9.3.1 Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2029)
  9.3.2 Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2029)
  9.3.3 China Market Size and Forecast (2018-2029)
  9.3.4 Japan Market Size and Forecast (2018-2029)
  9.3.5 Korea Market Size and Forecast (2018-2029)
  9.3.6 India Market Size and Forecast (2018-2029)
  9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
  9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
10.2 South America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
10.3 South America Cannabinoid Derived Pharmaceutical Market Size by Country
  10.3.1 South America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
  10.3.2 South America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
  10.3.3 Brazil Market Size and Forecast (2018-2029)
  10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Cannabinoid Derived Pharmaceutical Market Size by Country
  11.3.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
  11.3.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
  11.3.3 Turkey Market Size and Forecast (2018-2029)
  11.3.4 Egypt Market Size and Forecast (2018-2029)
  11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
  11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Cannabinoid Derived Pharmaceutical Market Drivers
12.2 Cannabinoid Derived Pharmaceutical Market Restraints
12.3 Cannabinoid Derived Pharmaceutical Trends Analysis
12.4 Porters Five Forces Analysis
  12.4.1 Threat of New Entrants
  12.4.2 Bargaining Power of Suppliers
  12.4.3 Bargaining Power of Buyers
  12.4.4 Threat of Substitutes
  12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
  12.5.1 Influence of COVID-19
  12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Cannabinoid Derived Pharmaceutical and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cannabinoid Derived Pharmaceutical
13.3 Cannabinoid Derived Pharmaceutical Production Process
13.4 Cannabinoid Derived Pharmaceutical Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel
  14.1.1 Direct to End-User
  14.1.2 Distributors
14.2 Cannabinoid Derived Pharmaceutical Typical Distributors
14.3 Cannabinoid Derived Pharmaceutical Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

LIST OF TABLES

Table 1. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Cara Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 4. Cara Therapeutics Inc Major Business
Table 5. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
Table 6. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Cara Therapeutics Inc Recent Developments/Updates
Table 8. Arena Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Arena Pharmaceuticals Major Business
Table 10. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 11. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Arena Pharmaceuticals Recent Developments/Updates
Table 13. Cannabics Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 14. Cannabics Pharmaceuticals Inc Major Business
Table 15. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product and Services
Table 16. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Cannabics Pharmaceuticals Inc Recent Developments/Updates
Table 18. Echo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Echo Pharmaceuticals Major Business
Table 20. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 21. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Echo Pharmaceuticals Recent Developments/Updates
Table 23. Gw Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Gw Pharmaceuticals Major Business
Table 25. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 26. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Gw Pharmaceuticals Recent Developments/Updates
Table 28. Inmed Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 29. Inmed Pharmaceuticals Major Business
Table 30. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 31. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Inmed Pharmaceuticals Recent Developments/Updates
Table 33. Insys Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 34. Insys Therapeutics Inc Major Business
Table 35. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
Table 36. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Insys Therapeutics Inc Recent Developments/Updates
Table 38. Larapharm Basic Information, Manufacturing Base and Competitors
Table 39. Larapharm Major Business
Table 40. Larapharm Cannabinoid Derived Pharmaceutical Product and Services
Table 41. Larapharm Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Larapharm Recent Developments/Updates
Table 43. Mgc Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 44. Mgc Pharmaceuticals Ltd Major Business
Table 45. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product and Services
Table 46. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Mgc Pharmaceuticals Ltd Recent Developments/Updates
Table 48. One World Cannabis Basic Information, Manufacturing Base and Competitors
Table 49. One World Cannabis Major Business
Table 50. One World Cannabis Cannabinoid Derived Pharmaceutical Product and Services
Table 51. One World Cannabis Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. One World Cannabis Recent Developments/Updates
Table 53. Orpheus Medica Basic Information, Manufacturing Base and Competitors
Table 54. Orpheus Medica Major Business
Table 55. Orpheus Medica Cannabinoid Derived Pharmaceutical Product and Services
Table 56. Orpheus Medica Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Orpheus Medica Recent Developments/Updates
Table 58. Receptor Life Sciences Basic Information, Manufacturing Base and Competitors
Table 59. Receptor Life Sciences Major Business
Table 60. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product and Services
Table 61. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Receptor Life Sciences Recent Developments/Updates
Table 63. Respirerx Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 64. Respirerx Pharmaceuticals Major Business
Table 65. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 66. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Respirerx Pharmaceuticals Recent Developments/Updates
Table 68. Tetra Bio-Pharma Basic Information, Manufacturing Base and Competitors
Table 69. Tetra Bio-Pharma Major Business
Table 70. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product and Services
Table 71. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Tetra Bio-Pharma Recent Developments/Updates
Table 73. Cardiol Therapeutics Basic Information, Manufacturing Base and Competitors
Table 74. Cardiol Therapeutics Major Business
Table 75. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product and Services
Table 76. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Cardiol Therapeutics Recent Developments/Updates
Table 78. United Cannabis Corporation Basic Information, Manufacturing Base and Competitors
Table 79. United Cannabis Corporation Major Business
Table 80. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product and Services
Table 81. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. United Cannabis Corporation Recent Developments/Updates
Table 83. Zynerba Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 84. Zynerba Pharmaceuticals Major Business
Table 85. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 86. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Zynerba Pharmaceuticals Recent Developments/Updates
Table 88. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 89. Global Cannabinoid Derived Pharmaceutical Revenue by Manufacturer (2018-2023) & (USD Million)
Table 90. Global Cannabinoid Derived Pharmaceutical Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 91. Market Position of Manufacturers in Cannabinoid Derived Pharmaceutical, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 92. Head Office and Cannabinoid Derived Pharmaceutical Production Site of Key Manufacturer
Table 93. Cannabinoid Derived Pharmaceutical Market: Company Product Type Footprint
Table 94. Cannabinoid Derived Pharmaceutical Market: Company Product Application Footprint
Table 95. Cannabinoid Derived Pharmaceutical New Market Entrants and Barriers to Market Entry
Table 96. Cannabinoid Derived Pharmaceutical Mergers, Acquisition, Agreements, and Collaborations
Table 97. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2023) & (K Units)
Table 98. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2024-2029) & (K Units)
Table 99. Global Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
Table 100. Global Cannabinoid Derived Pharmaceutical Consumption Value by Region (2024-2029) & (USD Million)
Table 101. Global Cannabinoid Derived Pharmaceutical Average Price by Region (2018-2023) & (US$/Unit)
Table 102. Global Cannabinoid Derived Pharmaceutical Average Price by Region (2024-2029) & (US$/Unit)
Table 103. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 104. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 105. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Global Cannabinoid Derived Pharmaceutical Average Price by Type (2018-2023) & (US$/Unit)
Table 108. Global Cannabinoid Derived Pharmaceutical Average Price by Type (2024-2029) & (US$/Unit)
Table 109. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 111. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application (2018-2023) & (USD Million)
Table 112. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application (2024-2029) & (USD Million)
Table 113. Global Cannabinoid Derived Pharmaceutical Average Price by Application (2018-2023) & (US$/Unit)
Table 114. Global Cannabinoid Derived Pharmaceutical Average Price by Application (2024-2029) & (US$/Unit)
Table 115. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 116. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 117. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 118. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 119. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2023) & (K Units)
Table 120. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2024-2029) & (K Units)
Table 121. North America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2023) & (USD Million)
Table 122. North America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 124. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 125. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 126. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 127. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2023) & (K Units)
Table 128. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2024-2029) & (K Units)
Table 129. Europe Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2023) & (USD Million)
Table 130. Europe Cannabinoid Derived Pharmaceutical Consumption Value by Country (2024-2029) & (USD Million)
Table 131. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 132. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 133. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 134. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 135. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2023) & (K Units)
Table 136. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2024-2029) & (K Units)
Table 137. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
Table 138. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value by Region (2024-2029) & (USD Million)
Table 139. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 140. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 141. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 142. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 143. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2023) & (K Units)
Table 144. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2024-2029) & (K Units)
Table 145. South America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2023) & (USD Million)
Table 146. South America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2024-2029) & (USD Million)
Table 147. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 148. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 149. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 150. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 151. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2023) & (K Units)
Table 152. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2024-2029) & (K Units)
Table 153. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
Table 154. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value by Region (2024-2029) & (USD Million)
Table 155. Cannabinoid Derived Pharmaceutical Raw Material
Table 156. Key Manufacturers of Cannabinoid Derived Pharmaceutical Raw Materials
Table 157. Cannabinoid Derived Pharmaceutical Typical Distributors
Table 158. Cannabinoid Derived Pharmaceutical Typical Customers

LIST OF FIGURES

Figure 1. Cannabinoid Derived Pharmaceutical Picture
Figure 2. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Type in 2022
Figure 4. Cannabinoid Receptor Type 1 (CB1) Examples
Figure 5. Cannabinoid Receptor Type 2 (CB2) Examples
Figure 6. Others Examples
Figure 7. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Application in 2022
Figure 9. Epilepsy Examples
Figure 10. Migraine Examples
Figure 11. Multiple Sclerosis Examples
Figure 12. Others Examples
Figure 13. Global Cannabinoid Derived Pharmaceutical Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Cannabinoid Derived Pharmaceutical Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Cannabinoid Derived Pharmaceutical Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Cannabinoid Derived Pharmaceutical Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Cannabinoid Derived Pharmaceutical by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Cannabinoid Derived Pharmaceutical Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Cannabinoid Derived Pharmaceutical Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Cannabinoid Derived Pharmaceutical Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Cannabinoid Derived Pharmaceutical Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Region (2018-2029)
Figure 55. China Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Cannabinoid Derived Pharmaceutical Market Drivers
Figure 76. Cannabinoid Derived Pharmaceutical Market Restraints
Figure 77. Cannabinoid Derived Pharmaceutical Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical in 2022
Figure 80. Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
Figure 81. Cannabinoid Derived Pharmaceutical Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source


More Publications